H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on INDV stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Folkes has given his Buy rating due to a combination of factors, foremost among them Indivior’s record quarterly and annual performance driven by strong SUBLOCADE momentum. He views the recent 20% revenue increase and near-doubling of adjusted EBITDA as evidence that the company’s earnings capacity has structurally improved, positioning Indivior as a durable cash generator rather than a short-term recovery story.
He also highlights accelerating prescription and patient trends, supported by a successful direct-to-consumer campaign and underpenetration of long-acting injectables in opioid use disorder, which together suggest ample room for sustained growth. Management’s 2026 outlook, calling for solid revenue gains, roughly 30% EBITDA growth, and substantial margin expansion, underpins his confidence in the $48 price target and supports the continued Buy recommendation.